Ursula Matulonis

Ursula Matulonis leads the gynecologic oncology program at Dana-Farber Cancer Institute and is internationally recognized for her contributions to PARP inhibitor therapy in ovarian cancer. She has led pivotal studies defining PARP inhibitor use in platinum-resistant settings and combination approaches to overcome resistance. Her research spans biomarker development, tumor biology of platinum-resistant disease, and the sequencing of targeted agents. She has shaped NCCN and international ovarian cancer clinical practice guidelines.